

MYBIOTICS

DEVELOPING MICROBIOME PHARMACEUTICALS

CLOSING THE CLINICAL GAP

MyBiotics is a Microbiome company developing live biotherapeutics drugs based on the company's unique delivery and colonization technologies, MyCrobe and SuperDonor. These technologies resolve some of the most critical challenges enabling superior clinical outcomes.

SELECTED PRODUCTS

MBX-SD-201 Fighting *Clostridium difficile* infection

With an estimated market of \$1.6B and approximately 700,000 cases a year in the US and up to 30,000 deaths this antibiotic resistant bacteria was the first to be treated using a microbiome related solution, the highly efficient fecal transplant. We are using SuperDonor technology to create a feces-free, safe and clinically efficient product for *C. difficile* patients.

THE HUMAN MICROBIOME

The human body consists of at least two times more bacterial cells than human cells, creating a network of bacterial-human cell interactions that greatly affect our health status and even our behavioral patterns. MyBiotics technology enables efficient microbiome therapeutics.

MBX-MC-103 Anti inflammatory

A unique combination of MyBiotics technologies and the microbiome capability to reduce inflammation will be the key in generating a long list of anti-inflammatory products. Our future anti-inflammatory product is designed to reduce inflammation in various health conditions, such as IBD, Crohn's disease and others.

MyBiotics technologies will make our product clinically superior

MYCROBE

MyCrobe is a proven method for targeting and colonization of live bacteria within the human body and therefore can solve unmet clinical challenges. MyCrobe technology is used as a generic platform solution for colonization of specifically selected beneficial bacteria.

SUPERDONOR

To replace the highly efficient and controversial treatment of Fecal Microbiota Transplant (FMT) we have developed our 2nd generation technology for improved bacterial growth, delivery and colonization. This revolutionary technology comprises of selected human-derived **multi-species composition**. This composition provides a powerful healing, microbiome restoration and screening tool to replace FMT and allow long term recovery treatment for a variety of medical indications.

Robust Delivery and Colonization in-vivo

survival in extreme pH - different strains

Acid tolerance of probiotic capsules vs. MyBiotics technology




Fig 1: survival in extreme pH - MyBiotics vs. commercial products

Bacteria Colonization In The Gut (Mice)

Unprecedented bacteria survival and colonization survival of *L. plantarum* in GI tract of spe mice





Fig 2: MyBiotics bacteria colonization vs. Commercial products (Mice)

- > **Proven colonization**
Stable population observed for 14 days following treatment
- > **Survival**
Significantly improved survival compared to commercial products
- > **Robustness**
Various animal models, aerobic and anaerobic bacteria



GO TO MARKET AND PRODUCT PIPELINE

Short time to market

MyBiotics approach is to develop strong and unique live biotherapeutics products to be developed and supported with results from clinical trials. This approach creates an aggressive marketing process for its initial product set to back up the company's R&D and efforts to keep its technological and scientific edge.

PRODUCT / TECHNOLOGY //

Product	Indication	discovery	Development & POC	Preclinical and in Human	Phase 1	Phase 2
MBX-SD-201	CDI	●	●			
MBX-MC-101	AAD	●		●		
MBX-MC-103	Anti inflammation	●	●			